Gary Lyman MD MPH FASCO FRCP(Edin) FACP
@glyman.bsky.social
Duke University School of Medicine
Fred Hutchinson Cancer Center
Distinguished Emeritus Member @ash-hematology.bsky.social
https://en.wikipedia.org/wiki/Gary_Herbert_Lyman
https://scholars.duke.edu/person/gary.lyman
Fred Hutchinson Cancer Center
Distinguished Emeritus Member @ash-hematology.bsky.social
https://en.wikipedia.org/wiki/Gary_Herbert_Lyman
https://scholars.duke.edu/person/gary.lyman
The MAHA Pipe Dream Is Going to Hurt MAGA the Most www.nytimes.com/2025/12/23/o...
Opinion | The MAHA Pipe Dream Is Going to Hurt MAGA the Most
www.nytimes.com
December 24, 2025 at 3:19 PM
The MAHA Pipe Dream Is Going to Hurt MAGA the Most www.nytimes.com/2025/12/23/o...
Measles 2025 | New England Journal of Medicine www.nejm.org/doi/full/10.... Measles is highly contagious; Measles vaccine has a long safety history and is highly effective against all circulating measles genotypes.
Measles 2025 | NEJM
In this article on measles, the authors review the epidemiology, clinical presentation,
and associated illnesses as well as treatment and prevention strategies.
www.nejm.org
December 18, 2025 at 1:14 AM
Measles 2025 | New England Journal of Medicine www.nejm.org/doi/full/10.... Measles is highly contagious; Measles vaccine has a long safety history and is highly effective against all circulating measles genotypes.
Statistics in Medicine — What’s in an Estimand? | New England Journal of Medicine www.nejm.org/doi/full/10.... “Per-protocol” or “as-treated” effects are sometimes reported in secondary analyses.
Statistics in Medicine — What’s in an Estimand? | NEJM
Recent articles on GLP-1 receptor agonists have presented as part of secondary analyses
an effect estimate that may be unfamiliar to some Journal readers: the “trial-product
estimand.”
www.nejm.org
December 18, 2025 at 1:07 AM
Statistics in Medicine — What’s in an Estimand? | New England Journal of Medicine www.nejm.org/doi/full/10.... “Per-protocol” or “as-treated” effects are sometimes reported in secondary analyses.
Reposted by Gary Lyman MD MPH FASCO FRCP(Edin) FACP
Bless you, Haley Stevens!
"Rep. Haley Stevens filed articles of impeachment against HHS Sec 🧠🐛, calling him 'the biggest self-created threat 2 our health & safety. RFK Jr. has got to go ... He's turned his back on #science & #publichealth & on the American people."
share.google/e6BHIqkJo2IR...
"Rep. Haley Stevens filed articles of impeachment against HHS Sec 🧠🐛, calling him 'the biggest self-created threat 2 our health & safety. RFK Jr. has got to go ... He's turned his back on #science & #publichealth & on the American people."
share.google/e6BHIqkJo2IR...
House Democrat files articles of impeachment against RFK Jr.
Rep. Haley Stevens (D-Mich.) said Wednesday she filed articles of impeachment against Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., calling him “the biggest self-created threat t…
share.google
December 11, 2025 at 5:47 AM
Bless you, Haley Stevens!
"Rep. Haley Stevens filed articles of impeachment against HHS Sec 🧠🐛, calling him 'the biggest self-created threat 2 our health & safety. RFK Jr. has got to go ... He's turned his back on #science & #publichealth & on the American people."
share.google/e6BHIqkJo2IR...
"Rep. Haley Stevens filed articles of impeachment against HHS Sec 🧠🐛, calling him 'the biggest self-created threat 2 our health & safety. RFK Jr. has got to go ... He's turned his back on #science & #publichealth & on the American people."
share.google/e6BHIqkJo2IR...
Current and Emerging Approaches to Evaluating Influenza Vaccine Performance | New England Journal of Medicine www.nejm.org/doi/full/10.... "incremental benefit of high-dose vaccine supporting recommendation that higher-dose are preferred over standard-dose vaccines for adults >=65"
Current and Emerging Approaches to Evaluating Influenza Vaccine Performance | NEJM
Randomized, placebo-controlled trials are widely accepted as the scientific reference
standard to determine a causal association between an intervention and an outcome.
They are pivotal for product...
www.nejm.org
December 11, 2025 at 1:23 AM
Current and Emerging Approaches to Evaluating Influenza Vaccine Performance | New England Journal of Medicine www.nejm.org/doi/full/10.... "incremental benefit of high-dose vaccine supporting recommendation that higher-dose are preferred over standard-dose vaccines for adults >=65"
Reposted by Gary Lyman MD MPH FASCO FRCP(Edin) FACP
⚠️ On Jan. 1, millions of people in the U.S. will face skyrocketing health care costs. Monthly premiums could double or triple. Many cancer patients may no longer be able to afford their care.
We can stop this. Call your members of Congress & urge them to extend the enhanced health care tax credits.
We can stop this. Call your members of Congress & urge them to extend the enhanced health care tax credits.
On January 1, health care costs will skyrocket for millions. Your call is needed now.
ACS CAN is the leading cancer advocacy organization that is working every day to make cancer issues a national priority.
act.fightcancer.org
December 10, 2025 at 5:05 PM
⚠️ On Jan. 1, millions of people in the U.S. will face skyrocketing health care costs. Monthly premiums could double or triple. Many cancer patients may no longer be able to afford their care.
We can stop this. Call your members of Congress & urge them to extend the enhanced health care tax credits.
We can stop this. Call your members of Congress & urge them to extend the enhanced health care tax credits.
Reposted by Gary Lyman MD MPH FASCO FRCP(Edin) FACP
Fred Hutch at #SABCS25: Catch Dr. Sara Hurvitz present "Safety analysis of ASCENT-03, a phase 3 study of sacituzumab govitecan" 👉 https://bit.ly/4oKawKi
December 10, 2025 at 5:30 PM
Fred Hutch at #SABCS25: Catch Dr. Sara Hurvitz present "Safety analysis of ASCENT-03, a phase 3 study of sacituzumab govitecan" 👉 https://bit.ly/4oKawKi
Reposted by Gary Lyman MD MPH FASCO FRCP(Edin) FACP
At age 7, Victor Roggli, MD, was told he wouldn’t live past 12. Today, he’s in his 44th year at Duke, where his research has transformed medical science and workplace safety.
🔗 Read more: https://medschool.duke.edu/stories/victor-roggli-cystic-fibrosis-survivor-asbestos-expert-karaoke-star
🔗 Read more: https://medschool.duke.edu/stories/victor-roggli-cystic-fibrosis-survivor-asbestos-expert-karaoke-star
December 10, 2025 at 8:52 PM
At age 7, Victor Roggli, MD, was told he wouldn’t live past 12. Today, he’s in his 44th year at Duke, where his research has transformed medical science and workplace safety.
🔗 Read more: https://medschool.duke.edu/stories/victor-roggli-cystic-fibrosis-survivor-asbestos-expert-karaoke-star
🔗 Read more: https://medschool.duke.edu/stories/victor-roggli-cystic-fibrosis-survivor-asbestos-expert-karaoke-star
Ianalumab plus Eltrombopag in Immune Thrombocytopenia | New England Journal of Medicine www.nejm.org/doi/full/10.... "Ianalumab plus eltrombopag led to a longer time to treatment failure than placebo plus eltrombopag"
Ianalumab plus Eltrombopag in Immune Thrombocytopenia | NEJM
Current second-line treatments for immune thrombocytopenia (ITP) require long-term
administration. Ianalumab, a monoclonal antibody targeting B cells, is being assessed
as a short-course second-lin...
www.nejm.org
December 11, 2025 at 1:09 AM
Ianalumab plus Eltrombopag in Immune Thrombocytopenia | New England Journal of Medicine www.nejm.org/doi/full/10.... "Ianalumab plus eltrombopag led to a longer time to treatment failure than placebo plus eltrombopag"
Reposted by Gary Lyman MD MPH FASCO FRCP(Edin) FACP
ASH 2025: Study Connects Agent Orange Exposure to Earlier and More Severe Cases of Myelodysplastic Syndrome
@ash.hematology.org @mikkaelsekeres.bsky.social
oncodaily.com/voices/agent...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #MDS #AgentOrange #ASH #ASH25 #ASH2025
@ash.hematology.org @mikkaelsekeres.bsky.social
oncodaily.com/voices/agent...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #MDS #AgentOrange #ASH #ASH25 #ASH2025
ASH 2025: Study Connects Agent Orange Exposure to Earlier and More Severe Cases of Myelodysplastic Syndrome - OncoDaily
ASH 2025: Study Connects Agent Orange Exposure to Earlier and More Severe Cases of Myelodysplastic Syndrome / Agent Orange, American Society of Hematology,
oncodaily.com
December 9, 2025 at 8:58 PM
ASH 2025: Study Connects Agent Orange Exposure to Earlier and More Severe Cases of Myelodysplastic Syndrome
@ash.hematology.org @mikkaelsekeres.bsky.social
oncodaily.com/voices/agent...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #MDS #AgentOrange #ASH #ASH25 #ASH2025
@ash.hematology.org @mikkaelsekeres.bsky.social
oncodaily.com/voices/agent...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #MDS #AgentOrange #ASH #ASH25 #ASH2025
Reposted by Gary Lyman MD MPH FASCO FRCP(Edin) FACP
Always fun to hear "Vogel New York's" questions at #SABCS25. It's like the official start of the conference. ;) #breastcancer #SABCS2025 @thankscancer.bsky.social #CanSky
December 9, 2025 at 11:17 PM
Always fun to hear "Vogel New York's" questions at #SABCS25. It's like the official start of the conference. ;) #breastcancer #SABCS2025 @thankscancer.bsky.social #CanSky
Reposted by Gary Lyman MD MPH FASCO FRCP(Edin) FACP
The Bumpy Road to Progress: Changes in the Management of the Axilla—Armando E. Giuliano delivered the William L. McGuire Award Lecture this morning at #SABCS25.
December 10, 2025 at 7:24 PM
Congratulations Armando!
The Bumpy Road to Progress: Changes in the Management of the Axilla—Armando E. Giuliano delivered the William L. McGuire Award Lecture this morning at #SABCS25.
December 10, 2025 at 8:19 PM
Congratulations Armando!
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer | New England Journal of Medicine www.nejm.org/doi/full/10.... "An important identified risk of T-DXd is interstitial lung disease, which requires appropriate monitoring and management"
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer | NEJM
Patients with human epidermal growth factor receptor 2 (HER2)–positive early breast
cancer and residual disease after neoadjuvant therapy are at high risk for recurrence.
In a phase 3, open-label, ...
www.nejm.org
December 10, 2025 at 8:18 PM
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer | New England Journal of Medicine www.nejm.org/doi/full/10.... "An important identified risk of T-DXd is interstitial lung disease, which requires appropriate monitoring and management"
A Challenge for Our Nation’s Academic Institutions & Health Care Systems, Part 2 open.substack.com/pub/robcalif... Continuation of this important discussion
A Challenge for Our Nation’s Academic Institutions & Health Care Systems, Part 2
Factors Driving Disparities in Health and Healthcare
open.substack.com
December 10, 2025 at 4:30 PM
A Challenge for Our Nation’s Academic Institutions & Health Care Systems, Part 2 open.substack.com/pub/robcalif... Continuation of this important discussion
Reposted by Gary Lyman MD MPH FASCO FRCP(Edin) FACP
AACR Announces 2025 Breast Cancer Research Award Recipients Ahead of SABCS 2025
@theaacr.bsky.social
@sabcs.bsky.social
@stolaney1.bsky.social
oncodaily.com/industry/aac...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #AACR #BreastCancer #SABCS #SABCS2025
@theaacr.bsky.social
@sabcs.bsky.social
@stolaney1.bsky.social
oncodaily.com/industry/aac...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #AACR #BreastCancer #SABCS #SABCS2025
AACR Announces 2025 Breast Cancer Research Award Recipients Ahead of SABCS 2025 - OncoDaily
AACR Announces 2025 Breast Cancer Research Award Recipients Ahead of SABCS 2025 / AACR, Breast Cancer, OncoDaily, onoclogy, SABCS 2025
oncodaily.com
December 6, 2025 at 5:30 PM
AACR Announces 2025 Breast Cancer Research Award Recipients Ahead of SABCS 2025
@theaacr.bsky.social
@sabcs.bsky.social
@stolaney1.bsky.social
oncodaily.com/industry/aac...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #AACR #BreastCancer #SABCS #SABCS2025
@theaacr.bsky.social
@sabcs.bsky.social
@stolaney1.bsky.social
oncodaily.com/industry/aac...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #AACR #BreastCancer #SABCS #SABCS2025
Reposted by Gary Lyman MD MPH FASCO FRCP(Edin) FACP
Fred Hutch at #ASH25: Catch Dr. Jennifer Huang present "Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic #leukemia" #CLL 👉 https://bit.ly/4rTooEO
December 8, 2025 at 2:51 PM
Fred Hutch at #ASH25: Catch Dr. Jennifer Huang present "Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic #leukemia" #CLL 👉 https://bit.ly/4rTooEO
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab | New England Journal of Medicine www.nejm.org/doi/full/10.... "incidence of adverse events of grade 3 or above was high and was consistent with previous observations for each agent as monotherapy"
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab | NEJM
Patients with plasmacytomas that are noncontiguous with bone marrow (true extramedullary
myeloma) are at high risk for disease progression or relapse. Phase 1 of the RedirecTT-1
study showed promis...
www.nejm.org
December 7, 2025 at 11:35 PM
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab | New England Journal of Medicine www.nejm.org/doi/full/10.... "incidence of adverse events of grade 3 or above was high and was consistent with previous observations for each agent as monotherapy"
A Challenge for our Nation’s Academic Institutions & Health Care Systems, Part 1 open.substack.com/pub/robcalif... Thoughtful and timely discussion of our current situation in health care
A Challenge for our Nation’s Academic Institutions & Health Care Systems, Part 1
The Gap in Prevention and Primary Care
open.substack.com
December 5, 2025 at 9:52 PM
A Challenge for our Nation’s Academic Institutions & Health Care Systems, Part 1 open.substack.com/pub/robcalif... Thoughtful and timely discussion of our current situation in health care
Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025–2026 | New England Journal of Medicine www.nejm.org/doi/full/10.... "Ongoing peer-reviewed evidence supports the safety and effectiveness of immunizations against Covid-19, RSV, and influenza during the 2025–2026 season."
Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025–2026 | NEJM
Changes in the vaccine advisory process in the United States have disrupted immunization
guidance, which reinforces the need for independent evidence review to inform decisions
regarding immunizati...
www.nejm.org
December 4, 2025 at 1:22 AM
Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025–2026 | New England Journal of Medicine www.nejm.org/doi/full/10.... "Ongoing peer-reviewed evidence supports the safety and effectiveness of immunizations against Covid-19, RSV, and influenza during the 2025–2026 season."
The New U.S. Global Health Strategy — A Reset of America’s Health Cooperation | New England Journal of Medicine www.nejm.org/doi/full/10.... Renewed commitments to regional and global partnerships and thoughtful transitions could ..shore up improvements in health outcomes from years of investment"
The New U.S. Global Health Strategy — A Reset of America’s Health Cooperation | NEJM
The U.S. administration recently unveiled its new approach to global health. A retreat from multilateralism, a geopolitical emphasis, and rushed transitions could threaten progress.
www.nejm.org
December 4, 2025 at 1:18 AM
The New U.S. Global Health Strategy — A Reset of America’s Health Cooperation | New England Journal of Medicine www.nejm.org/doi/full/10.... Renewed commitments to regional and global partnerships and thoughtful transitions could ..shore up improvements in health outcomes from years of investment"
A Threat to Evidence-Based Vaccine Policy and Public Health Security at the FDA | New England Journal of Medicine www.nejm.org/doi/full/10.... "If the goal is to.... insist on open deliberation, solid evidence, and procedures the public can see and trust"
A Threat to Evidence-Based Vaccine Policy and Public Health Security at the FDA | NEJM
Twelve former commissioners of the FDA express concern that the agency’s recent moves will undermine a regulatory model designed to ensure vaccine safety, effectiveness, and availability.
www.nejm.org
December 4, 2025 at 1:10 AM
A Threat to Evidence-Based Vaccine Policy and Public Health Security at the FDA | New England Journal of Medicine www.nejm.org/doi/full/10.... "If the goal is to.... insist on open deliberation, solid evidence, and procedures the public can see and trust"
Restoring Confidence in Public Health | New England Journal of Medicine www.nejm.org/doi/full/10.... "Because public health is critical for sustaining human well-being, all of us must have the courage to take on its current challenges"
Restoring Confidence in Public Health | NEJM
A confluence of interrelated factors has put past progress in public health at serious
risk in the United States. How did we get here, and what can public health professionals
do about it?
www.nejm.org
November 27, 2025 at 2:02 PM
Restoring Confidence in Public Health | New England Journal of Medicine www.nejm.org/doi/full/10.... "Because public health is critical for sustaining human well-being, all of us must have the courage to take on its current challenges"
Kennedy Says He Told C.D.C. to Change Website’s Language on Autism and Vaccines www.nytimes.com/2025/11/21/u...
Kennedy Says He Told C.D.C. to Change Website’s Language on Autism and Vaccines
www.nytimes.com
November 21, 2025 at 8:02 PM
Kennedy Says He Told C.D.C. to Change Website’s Language on Autism and Vaccines www.nytimes.com/2025/11/21/u...